# Cancer Center Support Grant

> **NIH NIH P30** · DUKE UNIVERSITY · 2024 · $201,250

## Abstract

PROJECT SUMMARY/ABSTRACT – OVERALL
The Duke Comprehensive Cancer Center was founded as a matrix center within the Duke University School of
Medicine in 1972 and the Duke Cancer Institute (DCI) was created as a new administrative entity within Duke
Health in October 2010, with authority and responsibility for all cancer-related activities at Duke University and
in the Duke University Health System. The DCI was started with significant investments from Duke Health,
including a new $243M clinical care outpatient facility, over $60 million of new funds available to support new
initiatives, and a commitment for ongoing annual investment by the Duke Health System. DCI faculty include
well-established and funded experts spanning the full spectrum of cancer research fields, from intracellular
signaling to cancer genomics to therapeutic development and testing to population science. DCI programmatic
activities support the career development of the next generation of cancer experts and provide platforms for
multi-disciplinary scientific teams to develop and test new hypotheses. During the most recent funding period,
the DCI structure has continued to evolve and mature, currently consisting of 304 members from 34 departments
within 7 schools at Duke University (Medicine, Nursing, Arts and Sciences, Engineering, Public Policy,
Environment, and Business) and organized as 8 multi-disciplinary research programs (2 basic discovery, 1
population science, and 5 translational/clinical) whose work is supported by 14 Shared Resources (8 lab-based
and 6 supporting translational/clinical/population research activities). In addition to Program and Shared
Resource leaders, DCI senior leadership, which includes an Executive Director, Deputy Director, 7 Associate
Directors, and 8 other key leaders, provides oversight and direction of DCI initiatives. DCI members are currently
supported by over $111M of external cancer-related grant support (direct costs), over $63M of which is peer-
reviewed, including 32 peer-reviewed, multi-investigator grants (involving 81 subprojects/cores) and 61 training
and fellowship awards. DCI members published over 5,750 cancer-focused papers during the past funding
period, ~40% of which represent collaborative efforts between DCI investigators. On average, ~7,000 new
cancer patients are seen each year at the Duke University Hospital. In 2018, DCI Programs enrolled over 4,000
patients on clinical trials, including nearly 2,000 interventional accruals and 770 therapeutic accruals. DCI is
heavily engaged in both community outreach/engagement and educating the next generation of cancer clinicians
and scientists. Duke Health support of the DCI included a total of over $65M of additional investment in the most
recent funding period, including support for recruitment, retention, and protected academic time for DCI faculty.
The DCI completed an extensive 5-year Strategic Planning process, identifying strategic goals and priorities that
enable the DCI m...

## Key facts

- **NIH application ID:** 11010037
- **Project number:** 3P30CA014236-50S2
- **Recipient organization:** DUKE UNIVERSITY
- **Principal Investigator:** Michael B Kastan
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $201,250
- **Award type:** 3
- **Project period:** 1997-01-01 → 2025-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11010037

## Citation

> US National Institutes of Health, RePORTER application 11010037, Cancer Center Support Grant (3P30CA014236-50S2). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/11010037. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
